Kos Biotechnology Partners, a global investment firm focused on life sciences, has announced the completion of a financing round in Epikast, a provider of technology-driven commercial and clinical support services for the biopharmaceutical sector. This investment represents the first deployment from Kos’ inaugural fund, which targets opportunities across multiple stages, from early formation to scaling established healthcare platforms.
Health Technology Insights: Cone Health Announces New CEO
Kos led the financing round with participation from both new and existing investors. As part of the transaction, Alex Tzoukas, Managing Partner and Co-Founder of Kos Biotechnology Partners, has been appointed to Epikast’s Board of Directors, further strengthening the company’s governance as it enters its next phase of growth.
The new funding will be used to further develop Epikast’s proprietary technology and expand its specialized service teams. Operating through a hub in Greece, Epikast combines deep medical expertise with efficient operational delivery to support biopharmaceutical companies worldwide. This model allows the company to provide high-quality commercial and clinical services while maintaining a cost-effective structure.
Health Technology Insights: AHN Offers Innovative Low-Dose Radiation Therapy for Osteoarthritis
Alex Tzoukas said that Epikast stood out as a strong first investment for the firm’s new fund. He noted that the company has built a distinct services platform that uses technology to address long-standing challenges in how biopharma companies connect with healthcare professionals and patients. Tzoukas added that Kos looks forward to supporting Epikast as it continues to grow and broaden its impact.
Dr. Stelios Papadopoulos, Chairman of Epikast, welcomed Kos Biotechnology Partners as the lead investor in the round. He said that Kos brings valuable industry knowledge and close ties to both the US and Greek life sciences communities, which align well with Epikast’s operating model. He also highlighted that Tzoukas joining the board adds important strategic perspective as the company scales.
Dr. Simos Simeonidis, Managing Partner and Co-Founder of Kos Biotechnology Partners, shared that the firm is pleased to partner with Papadopoulos and the broader Epikast team through its first fund investment. He pointed to Tzoukas’ background as an investor, banker, and operator as a meaningful addition to an already experienced board.
Dr. Vangelis Vergetis, Chief Executive Officer of Epikast, said the financing builds on the company’s strong momentum. He emphasized the importance of working with partners who bring experience and sound judgment, noting that Alex Tzoukas, Simos Simeonidis, and Nikos Kostaras will be valuable collaborators as Epikast moves into its next stage of development.
Epikast is a technology-enabled biopharmaceutical services company headquartered in New York, with core operations based in Athens, Greece. The company delivers remote commercial, medical, market access, and patient support services by combining trained medical professionals with its own technology platform. Epikast works with several top global pharmaceutical companies as well as emerging biotech firms supporting product launches and commercialization across the United States and Europe.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 24 December 2025
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
